Colinz Laboratories Limited has formally notified BSE that it does not qualify as a Large Corporate under the Securities and Exchange Board of India's regulatory framework. The pharmaceutical company submitted its confirmation regarding its status under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

SEBI Large Corporate Framework Compliance

The company confirmed that it does not fulfill the criteria specified in Para 2.2 of the SEBI circular related to the applicability of the framework for Large Corporates. This circular pertains to fund raising by issuance of debt securities by large entities and establishes specific thresholds and requirements for companies classified under this category.

Regulatory Disclosure Exemption

Since Colinz Laboratories does not meet the Large Corporate classification criteria, the company will be exempt from specific regulatory filing requirements. The exemption applies to both initial and annual disclosures mandated under the SEBI circular for the financial year ended March 31, 2026.

The confirmation eliminates the company's obligation to comply with enhanced disclosure norms and additional regulatory requirements typically imposed on entities classified as Large Corporates under the SEBI framework.

Official Authorization

The regulatory confirmation was officially authorized by key company officials. Director Vijaya Mani, holding DIN 11363910, and Chief Financial Officer Ganesh Chitte jointly signed the communication to BSE. The document bears the official company stamp, ensuring proper authentication of the regulatory submission.

The company requested BSE to take the confirmation on record, completing the necessary regulatory communication process for the financial year 2026.

Colinz Laboratories Limited announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating robust growth in profitability. The pharmaceutical formulations manufacturer reported a significant 56.8% year-on-year increase in net profit, reaching ₹8.36 crore compared to ₹5.33 crore in the corresponding quarter of the previous year.

Financial Performance Overview

The company's quarterly performance showed mixed results across different parameters. Revenue from operations stood at ₹143.41 crore for Q3FY26, representing a decline from ₹146.65 crore in Q3FY24. However, the addition of other income of ₹7.54 crore brought total income to ₹150.95 crore for the quarter.

Operational Efficiency and Cost Management

The company demonstrated improved operational efficiency during the quarter. Total expenses decreased to ₹138.34 crore from ₹144.06 crore in the corresponding quarter last year. Key expense categories showed varied performance, with employee benefit expenses declining to ₹58.42 crore from ₹68.70 crore year-on-year.

Profit before tax reached ₹12.61 crore, marking a 22.1% increase from ₹10.33 crore in Q3FY24. The company's tax provision for the quarter stood at ₹4.25 crore compared to ₹5.00 crore in the previous year.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Colinz Laboratories maintained steady performance with net profit at ₹34.33 crore, marginally lower than ₹34.62 crore in the corresponding period last year. Revenue from operations for the nine-month period totaled ₹438.82 crore compared to ₹507.63 crore in the previous year.

Earnings Per Share and Other Comprehensive Income

The company's earnings per share (EPS) for Q3FY26 improved to ₹0.33 from ₹0.21 in the corresponding quarter last year. For the nine-month period, EPS remained relatively stable at ₹1.36 compared to ₹1.37 in the previous year.

A notable highlight was the significant improvement in other comprehensive income, which reached ₹7.93 crore in Q3FY26 compared to a negative ₹12.11 crore in Q3FY24. This improvement was primarily driven by changes in fair value of investment in equity instruments.

Corporate Governance and Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 24, 2026. The meeting commenced at 3:30 PM and concluded at 6:15 PM. The results have been audited by Vora & Associates, Chartered Accountants, who issued an unqualified audit opinion.

Colinz Laboratories operates primarily in the pharmaceutical formulations manufacturing business with no other reportable segments. The company's results are available on the BSE website and the company's official website as per SEBI regulations.